Norges Bank Buys New Position in Amedisys, Inc. (NASDAQ:AMED)

Norges Bank acquired a new position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 914,864 shares of the health services provider's stock, valued at approximately $83,061,000. Norges Bank owned about 2.79% of Amedisys at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in AMED. National Bank of Canada FI raised its position in shares of Amedisys by 119.0% during the 3rd quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider's stock worth $5,365,000 after purchasing an additional 30,213 shares during the period. ABC Arbitrage SA acquired a new position in shares of Amedisys during the fourth quarter valued at $2,522,000. Geode Capital Management LLC grew its position in shares of Amedisys by 1.3% during the third quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider's stock worth $54,746,000 after acquiring an additional 7,071 shares during the last quarter. Quarry LP acquired a new stake in shares of Amedisys in the 3rd quarter worth about $2,569,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Amedisys by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider's stock valued at $33,400,000 after purchasing an additional 9,004 shares during the last quarter. Institutional investors and hedge funds own 94.36% of the company's stock.

Wall Street Analyst Weigh In

Separately, Stephens restated an "equal weight" rating and issued a $101.00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, Amedisys currently has an average rating of "Hold" and an average price target of $101.00.

Remove Ads

Amedisys Stock Performance

Shares of AMED traded down $0.19 during trading hours on Monday, reaching $91.70. 412,741 shares of the company's stock traded hands, compared to its average volume of 398,362. Amedisys, Inc. has a twelve month low of $82.15 and a twelve month high of $98.95. The business's fifty day simple moving average is $92.29 and its two-hundred day simple moving average is $92.21. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of 36.39, a P/E/G ratio of 1.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED - Get Free Report) last released its earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The company had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. Analysts predict that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.